• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

呼吸道病毒感染:了解 COVID-19。

Respiratory Virus Infections: Understanding COVID-19.

机构信息

WHO Collaborating Centre for Reference and Research on Influenza and Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.

Department of Medicine, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.

出版信息

Immunity. 2020 Jun 16;52(6):905-909. doi: 10.1016/j.immuni.2020.05.004. Epub 2020 May 20.

DOI:10.1016/j.immuni.2020.05.004
PMID:32497522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7237932/
Abstract

Respiratory viruses affect us throughout our lives, from infancy to old age, causing illnesses ranging from a common cold to severe pneumonia. They belong to several virus families, and although many features of infection with these diverse viruses are shared, some have unique characteristics. Here we explain what happens when we are infected by respiratory viruses, including SARS-CoV-2, which causes COVID-19.

摘要

呼吸道病毒在我们的一生中都会影响我们,从婴儿期到老年期,引起从普通感冒到严重肺炎等各种疾病。它们属于几种病毒家族,尽管感染这些不同病毒的许多特征是共同的,但有些病毒具有独特的特征。在这里,我们解释当我们感染呼吸道病毒时会发生什么,包括导致 COVID-19 的 SARS-CoV-2。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6123/7237932/5390a6229fb3/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6123/7237932/e1f97ef9b956/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6123/7237932/5390a6229fb3/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6123/7237932/e1f97ef9b956/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6123/7237932/5390a6229fb3/gr2_lrg.jpg

相似文献

1
Respiratory Virus Infections: Understanding COVID-19.呼吸道病毒感染:了解 COVID-19。
Immunity. 2020 Jun 16;52(6):905-909. doi: 10.1016/j.immuni.2020.05.004. Epub 2020 May 20.
2
Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures.人呼吸道和结膜中冠状病毒 SARS-CoV-2 的趋向性、复制能力和先天免疫反应:离体和在体培养分析。
Lancet Respir Med. 2020 Jul;8(7):687-695. doi: 10.1016/S2213-2600(20)30193-4. Epub 2020 May 7.
3
The trinity of COVID-19: immunity, inflammation and intervention.COVID-19 的三位一体:免疫、炎症和干预。
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
4
How does SARS-CoV-2 cause COVID-19?严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是如何引发2019冠状病毒病(COVID-19)的?
Science. 2020 Jul 31;369(6503):510-511. doi: 10.1126/science.abc6156.
5
Pathogenesis of COVID-19 from a cell biology perspective.从细胞生物学角度看 COVID-19 的发病机制。
Eur Respir J. 2020 Apr 16;55(4). doi: 10.1183/13993003.00607-2020. Print 2020 Apr.
6
Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.伊朗暴发期间 SARS-CoV-2 的免疫反应和发病机制:与 SARS 和 MERS 的比较。
Rev Med Virol. 2020 May;30(3):e2107. doi: 10.1002/rmv.2107. Epub 2020 Apr 8.
7
SARS-CoV-2: the emergence of a viral pathogen causing havoc on human existence.严重急性呼吸综合征冠状病毒2:一种对人类生存造成严重破坏的病毒病原体的出现。
J Genet. 2020;99(1). doi: 10.1007/s12041-020-01205-x.
8
Hypotension, Systemic Inflammatory Response Syndrome, and COVID-19: A Clinical Conundrum.低血压、全身炎症反应综合征与新型冠状病毒肺炎:一个临床难题。
Anesth Analg. 2020 Sep;131(3):e175-e176. doi: 10.1213/ANE.0000000000005062.
9
COVID-19: an Immunopathological View.新型冠状病毒肺炎:免疫病理学视角
mSphere. 2020 Apr 22;5(2):e00344-20. doi: 10.1128/mSphere.00344-20.
10
Cystic Fibrosis and COVID-19.囊性纤维化与2019冠状病毒病
South Med J. 2020 Sep;113(9):422. doi: 10.14423/SMJ.0000000000001140.

引用本文的文献

1
Vitamin D: A Nutraceutical Supplement at the Crossroad Between Respiratory Infections and COVID-19.维生素D:一种处于呼吸道感染和新冠肺炎交叉点的营养补充剂。
Int J Mol Sci. 2025 Mar 12;26(6):2550. doi: 10.3390/ijms26062550.
2
Outcomes and inflammation changes in different types of immunocompromised patients with critically ill COVID-19 admitted to ICU: a national multicenter study.不同类型免疫功能低下危重症 COVID-19 患者入住 ICU 的结局和炎症变化:一项全国多中心研究。
BMC Pulm Med. 2024 Oct 31;24(1):548. doi: 10.1186/s12890-024-03362-6.
3
Exploring Bioactive Phytomedicines for Advancing Pulmonary Infection Management: Insights and Future Prospects.

本文引用的文献

1
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
2
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
3
The many faces of the anti-COVID immune response.抗新冠病毒免疫反应的多面性。
探索用于推进肺部感染管理的生物活性植物药:见解与未来展望
Phytother Res. 2024 Dec;38(12):5840-5872. doi: 10.1002/ptr.8334. Epub 2024 Oct 9.
4
Notch4 regulatory T cells and SARS-CoV-2 viremia shape COVID19 survival outcome.Notch4调节性T细胞和SARS-CoV-2病毒血症影响COVID-19的生存结果。
Allergy. 2025 Feb;80(2):557-569. doi: 10.1111/all.16333. Epub 2024 Oct 3.
5
Breaking the Chain: Protease Inhibitors as Game Changers in Respiratory Viruses Management.打破链条:蛋白酶抑制剂在呼吸道病毒管理中的变革作用。
Int J Mol Sci. 2024 Jul 25;25(15):8105. doi: 10.3390/ijms25158105.
6
Microfluidic Immunoarray for Point-of-Care Detection of Cytokines in COVID-19 Patients.用于即时检测新冠肺炎患者细胞因子的微流控免疫阵列
ACS Omega. 2024 Jun 24;9(27):29320-29330. doi: 10.1021/acsomega.4c00735. eCollection 2024 Jul 9.
7
Repurposing Anticancer Drugs Targeting the MAPK/ERK Signaling Pathway for the Treatment of Respiratory Virus Infections.针对 MAPK/ERK 信号通路的抗癌药物再利用治疗呼吸道病毒感染。
Int J Mol Sci. 2024 Jun 25;25(13):6946. doi: 10.3390/ijms25136946.
8
Rapid and on-site wireless immunoassay of respiratory virus aerosols via hydrogel-modulated resonators.通过水凝胶调制谐振器对呼吸道病毒气溶胶进行快速现场无线免疫分析。
Nat Commun. 2024 May 13;15(1):4035. doi: 10.1038/s41467-024-48294-1.
9
Development of Respiratory Infection Prevention and Control Self-Efficacy Scale for Adults.成人呼吸道感染预防与控制自我效能量表的编制
J Multidiscip Healthc. 2024 Apr 30;17:1943-1952. doi: 10.2147/JMDH.S456939. eCollection 2024.
10
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?新冠病毒疫苗接种前后的多发性硬化症发病:HLA单倍型能否成为决定因素?
Int J Mol Sci. 2024 Apr 22;25(8):4556. doi: 10.3390/ijms25084556.
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20200678.
4
Mild or Moderate Covid-19.轻度或中度新冠病毒感染
N Engl J Med. 2020 Oct 29;383(18):1757-1766. doi: 10.1056/NEJMcp2009249. Epub 2020 Apr 24.
5
Cytokine release syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子释放综合征
Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17.
6
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.患者康复前伴随免疫反应的广度:非重症COVID-19病例报告
Nat Med. 2020 Apr;26(4):453-455. doi: 10.1038/s41591-020-0819-2.
7
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.与严重急性呼吸综合征冠状病毒1(SARS-CoV-1)相比,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在气溶胶和表面的稳定性
N Engl J Med. 2020 Apr 16;382(16):1564-1567. doi: 10.1056/NEJMc2004973. Epub 2020 Mar 17.
8
The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.新型冠状病毒肺炎(COVID-19)的潜伏期来自公开报告的确诊病例:估计和应用。
Ann Intern Med. 2020 May 5;172(9):577-582. doi: 10.7326/M20-0504. Epub 2020 Mar 10.
9
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)进入细胞依赖于 ACE2 和 TMPRSS2,可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
10
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情,该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.